Ozempic and Gastroparesis: Key Facts to Discuss with Your Doctor

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Risk Analysis

If you or someone you know has experienced delayed stomach emptying while taking Ozempic, you may be wondering how common this side effect is and what the FDA data shows. Building on a long tradition of rigorous pharmacovigilance, this page examines FAERS reports linking Ozempic to gastroparesis and outlines the key facts patients need for informed discussions with their healthcare provider.

Find Out If You Qualify for Compensation →

Ozempic and Gastroparesis: A Documented Association

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacological action involves slowing gastric emptying, a mechanism that contributes to glycemic control but also underlies a spectrum of gastrointestinal adverse effects. Among the most serious of these is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis can range from mild discomfort to severe malnutrition and hospitalization, and diagnosis typically involves gastric emptying scintigraphy or breath testing. The mechanistic pathway linking Ozempic to gastroparesis is rooted in its effect on GLP-1 receptors in the gut, which inhibit antral contractions and relax the pylorus, thereby slowing the transit of food from the stomach to the small intestine. While this effect is intended for diabetes management, prolonged or exaggerated slowing can result in clinically significant gastroparesis. Evidence from clinical trials demonstrates that gastrointestinal adverse reactions are common with Ozempic use. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, other gastrointestinal adverse reactions with a frequency of less than 5% were associated with Ozempic, including dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, with gastroparesis representing a severe manifestation of delayed gastric emptying.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not explicitly list gastroparesis as a separate warning or caution. Instead, the label describes gastrointestinal adverse reactions in general terms, noting that they occur more frequently with Ozempic than placebo and that discontinuation rates are higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The label also includes a warning for hypersensitivity reactions, such as anaphylaxis and angioedema, but does not specifically address the risk of gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may be relevant for patients who develop severe symptoms consistent with gastroparesis, as they may not have been adequately informed of this potential harm. For affected patients, settlement-related considerations often hinge on whether the manufacturer provided sufficient warnings to allow informed decision-making. In Florida, the statute of limitations for product liability claims, including those related to inadequate warnings, is generally four years from the date of injury or discovery of the injury. However, this timeline can vary based on specific circumstances, such as when the harm was reasonably discoverable. For gastroparesis, the timeline between exposure to Ozempic and documented harm can be variable, with symptoms often emerging during dose escalation or after prolonged use. Patients who experience persistent nausea, vomiting, or abdominal pain after starting Ozempic should seek medical evaluation to determine if gastroparesis is present, as early diagnosis may affect both clinical management and legal timelines. In summary, the evidence indicates a clear association between Ozempic use and gastrointestinal adverse reactions, including those consistent with gastroparesis. The mechanistic pathway through delayed gastric emptying is well-established, and clinical trial data show a dose-dependent increase in such events. However, the adequacy of warnings remains a concern, as the label does not explicitly mention gastroparesis. For Florida patients considering legal action, the statute of limitations is a key factor, and the timeline from exposure to harm should be carefully documented. Medical and legal professionals should work together to assess individual cases, considering the severity of symptoms, duration of use, and any prior warnings received.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Florida?

In Florida, the statute of limitations for product liability claims, including those related to inadequate warnings for Ozempic and gastroparesis, is generally four years from the date of injury or discovery of the injury. However, this timeline can vary based on specific circumstances, such as when the harm was reasonably discoverable. It is important to consult with a legal professional to determine the applicable deadline for your case.

Does Ozempic's prescribing information warn about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not explicitly list gastroparesis as a separate warning or caution. The label describes gastrointestinal adverse reactions in general terms and notes that they occur more frequently with Ozempic than placebo, but it does not specifically address the risk of gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.